American Association of Individual Investors1d
Which Is a Better Investment, AstraZeneca PLC or Intra-Cellular Therapies, Inc. Stock?
Learn more about whether AstraZeneca PLC or Intra-Cellular Therapies, Inc. is a better investment based on AAII's A+ Investor ...
AstraZeneca Rises Almost 9% in a Month: How to Play the Stock
AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...
pharmaphorum5d
Boehringer eyes third quarter FDA verdict for oral HER2 drug
AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) already has accelerated approval as a second-line treatment for HER2-mutated NSCLC and is dosed ...
Here’s Why AstraZeneca PLC (AZN) Traded Lower in Q4
Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter.
AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by Allworth Financial LP
Allworth Financial LP boosted its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 12.9% in the fourth quarter, ...
Cure Today5d
Understanding the FDA Approval of Enhertu in HER2-Low and -Ultralow Breast Cancer
Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...
precisionmedicineonline6d
FDA Accepts Boehringer Ingelheim's New Drug Application for HER2-Targeted Therapy in NSCLC
In a Phase Ib trial, 71 percent of patients responded to zongertinib and lived a median six months before disease progression or death.
BioSpace6d
5 Pharma Powerhouses Facing Massive Patent Cliffs—And What They’re Doing About It
Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...